Don't Just Read the News, Understand It.
Get Started
SubscribeLogin
Israel-Hamas Conflict
Heatwaves
Juneteenth
Social Media
Donald Trump
Artificial Intelligence
Music
Military
Republican Party
Immigration
War
United Nations
Senate
Published • loading... • Updated

Merck Launches Phase 3 Trial of Single-Dose Dengue Vaccine Candidate V181

Summary by contagionlive.com
Evaluating safety and efficacy against symptomatic, virologically confirmed dengue in children and adolescents.

1 Articles

All
Left
Center
Right
contagionlive.comcontagionlive.com

Merck Launches Phase 3 Trial of Single-Dose Dengue Vaccine Candidate V181

Evaluating safety and efficacy against symptomatic, virologically confirmed dengue in children and adolescents.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

contagionlive.com broke the news in on Monday, June 16, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

News
For You
SearchBlindspotLocal